We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

87 hedge funds and large institutions have $73.5M invested in Akebia Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

169% more call options, than puts

Call options by funds: $1.33M | Put options by funds: $494K

27% more capital invested

Capital invested by funds: $58M → $73.5M (+$15.5M)

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

14% more funds holding

Funds holding: 76 → 87 (+11)

2.42% more ownership

Funds ownership: 27% → 29.42% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
87
Holders Change
+11
Holders Change %
+14.47%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
23
Reduced
20
Closed
4
Calls
$1.33M
Puts
$494K
Net Calls
+$835K
Net Calls Change
-$500K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.66M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.44M
3
Morgan Stanley
Morgan Stanley
New York
+$954K
4
BlackRock
BlackRock
New York
+$682K
5
ECM
ExodusPoint Capital Management
New York
+$248K

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$748K
2
Millennium Management
Millennium Management
New York
-$462K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$314K
4
Federated Hermes
Federated Hermes
Pennsylvania
-$101K
5
JP Morgan Chase
JP Morgan Chase
New York
-$96.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$195K +$90.1K +88,302 +128%
Tudor Investment Corp
27
Tudor Investment Corp
Connecticut
$176K – – –
Creative Planning
28
Creative Planning
Kansas
$137K +$267 +262 +0.2%
XT
29
XTX Topco
Cayman Islands
$124K -$39.6K -38,861 -28%
Jane Street
30
Jane Street
New York
$121K +$38.1K +37,372 +62%
HighTower Advisors
31
HighTower Advisors
Illinois
$119K +$1.02K +1,000 +1%
OCM
32
Orchard Capital Management
Illinois
$108K +$20.4K +20,000 +30%
Charles Schwab
33
Charles Schwab
California
$99K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$89.1K +$1 +1 +0%
CSS
35
Cubist Systematic Strategies
Connecticut
$83.9K +$69K +67,627 New
MFS
36
Mirabella Financial Services
United Kingdom
$81K +$66.6K +65,300 New
Franklin Resources
37
Franklin Resources
California
$80.7K – – –
TWC
38
TD Waterhouse Canada
Ontario, Canada
$75.5K – – –
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$75K – – –
VF
40
Virtu Financial
New York
$74K +$60.7K +59,479 New
EDRH
41
Edmond de Rothschild Holding
Switzerland
$62K – – –
Group One Trading
42
Group One Trading
Illinois
$61.6K -$39.5K -38,694 -44%
CAMG
43
CWA Asset Management Group
Florida
$60.8K – – –
SOW
44
State of Wyoming
Wyoming
$49.3K -$35K -34,285 -46%
Squarepoint
45
Squarepoint
New York
$37.9K +$31.2K +30,556 New
RJA
46
Raymond James & Associates
Florida
$37.1K +$9.89K +9,696 +48%
WE
47
Wealth Effects
Massachusetts
$36.6K – – –
Invesco
48
Invesco
Georgia
$36.2K +$5.46K +5,353 +22%
EP
49
Eudaimonia Partners
Tennessee
$33.2K -$408 -400 -1%
GCM
50
Graham Capital Management
Connecticut
$29.3K +$24.1K +23,633 New
1
2
3 4

AKBA Hedge Fund Activity: Q4 2023 in Review

87 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2023, worth a combined $73.5M — up 27% from $58M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AKBA positions and 4 closed out — a net gain of 11 holders — while 23 added to existing stakes and 20 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.66M. The largest seller was Victory Capital Management, cutting an estimated $748K.

  • 87 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2023, up from 76 in Q3 2023.
  • Funds reported $73.5M of Akebia Therapeutics stock for Q4 2023, up 27% quarter-over-quarter.
  • 15 funds opened new Akebia Therapeutics positions in Q4 2023 and 4 closed out, a net change of +11 holders.
  • The largest Akebia Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $1.66M added.
  • The largest Akebia Therapeutics seller in Q4 2023 was Victory Capital Management, an estimated $748K sold.

Based on aggregated 13F filings for Q4 2023.